Get the Stockscreener App
25.53
3.41%
-0.90
After Hours:
25.43
-0.10
-0.39%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.53, with a volume of 111.37M.
It is down -3.41% in the last 24 hours and up +1.88% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$26.43
Open:
$26.44
24h Volume:
111.37M
Relative Volume:
1.64
Market Cap:
$145.16B
Revenue:
$62.79B
Net Income/Loss:
$9.84B
P/E Ratio:
14.88
EPS:
1.7156
Net Cash Flow:
$10.38B
1W Performance:
+0.79%
1M Performance:
+1.88%
6M Performance:
+4.63%
1Y Performance:
+1.11%
1-Day Range:
$24.92
$26.50
1-Week Range:
$24.92
$26.65
52-Week Range:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.53 | 150.27B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,054.29 | 950.68B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
209.30 | 516.00B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.67 | 401.99B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.03 | 259.40B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
98.27 | 248.85B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast - Yahoo Finance
Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17 - ts2.tech
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Pfizer (NYSE:PFE) Stock Price Down 3.3% After Analyst Downgrade - MarketBeat
Pfizer Stands By Vaccines Investment Despite Political ‘Anomaly’ - Citeline News & Insights
Tepid 2026 outlook dents Pfizer shares - Yahoo Finance
Pfizer ’26 Guidance Puts Emphasis On The Long Term For A Return To Growth - Citeline News & Insights
Pfizer outlook, Humana leadership shake-up, Kraft Heinz's new CEO - Yahoo Finance
PFIZER INC : Jefferies reiterates its Buy rating - marketscreener.com
Pfizer Q4 2026 Financial Guidance (NYSE:PFE) 2025-12-16 - Seeking Alpha
Market movers: Circle, Pfizer, Reconnaissance Energy Africa... - Proactive Investors
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector - Markets Financial Content
S&P 500 Stays Range-Bound as NFP Cools Without Forcing Panic Fed Cuts - Investing.com
Pfizer faces challenging years on fading COVID sales, margin pressure - Reuters
Pfizer forecasts 2026 profit below expectations on lower COVID product sales - WKZO
Pfizer leads COVID-19 vaccine peers lower after revamped guidance - Seeking Alpha
Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue - Yahoo Finance
Pfizer sees flat 2026 sales as it rebuilds drug pipeline - The Detroit News
Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures - Pharmaceutical Technology
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus - ts2.tech
Rothschild & Co Redburn Adjusts Pfizer Price Target to $23 From $24, Maintains Neutral Rating - marketscreener.com
Pfizer shares fall after it forecasts 2026 revenue below estimates - Proactive Investors
Top Midday Stories: Pfizer Falls Following 2026 Outlook; Netflix-iHeartMedia Exclusive Deal; Apple's Possible iPhone Lineup Expansion - marketscreener.com
Pfizer CEO Defends Vaccines, Promises Growth by End of Decade - Barron's
Pfizer stock price target lowered to $27 at BofA on faster Covid product erosion - Investing.com Canada
Pfizer Forecasts Flat 2026 Sales as It Builds Drug Pipeline - Bloomberg.com
Why Pfizer (PFE) Stock Is Sliding Today - Yahoo Finance
Pfizer Shares Under Pressure Amid Financial Challenges - TipRanks
Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline - Yahoo Finance
Pfizer Shares Fall as 2026 Outlook Reflects Weaker COVID-19 Drug Demand - Tokenist
Pfizer drops 3% on weak 2026 outlook - breakingthenews.net
PFIZER INC : JP Morgan is Neutral - marketscreener.com
Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts - Benzinga
Herbert Smith Freehills Kewei advises Fosun Pharma on international licence agreements with Pfizer and Sitala - Legal Desire Media and Insights
Pfizer Sets A Lower Bar For 2026 Earnings And Revenue - Finimize
Pfizer Issues 2026 Earnings Outlook Below Street Views, Expects COVID-19 Revenue to Decline - marketscreener.com
Pfizer : Analyst and Investor Call to Review Pfizer Full-Year 2026 Financial Guidance Event Announcement - marketscreener.com
Pfizer (PFE) Stock: Why Shares Rose Despite Grim 2026 Profit Warning - Blockonomi
Pfizer sets out 2026 outlook, signalling softer revenue and earnings - MSN
Pfizer Stock (PFE) Plunges on Weaker 2026 Profit Outlook as COVID-19 Franchise Fades - TipRanks
Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43 - ts2.tech
Pfizer drops as drugmaker predicts little sales growth in 2026 - The Edge Malaysia
Pfizer’s stock drops after drug giant lowers its revenue forecast - MarketWatch
Pfizer stock edges higher on 2026 guidance. Expect a rough year for Covid vaccine sales - MSN
Pfizer Stock Edges Higher on 2026 Guidance as Covid Vaccine Sales Slide - Barron's
Pfizer falls after 2026 guidance falls short of analysts’ expectations - Sherwood News
Pfizer Updates 2025 Revenue Guidance, Issues 2026 Outlook - marketscreener.com
Pfizer Revises 2025 Revenue Guidance to $62 Billion - TipRanks
Pfizer projects 2026 revenue of $59.5-62.5 billion, adjusts 2025 outlook By Investing.com - Investing.com South Africa
Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales. - Barron's
Pfizer Revises Annual Revenue Guidance Below View, Backs Profit Expectations; Initiates 2026 Outlook - Nasdaq
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):